IBDEI2QD ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,43540,1,3,0)
;;=3^Psychomtr Dfct s/p Unsp Cebrvsc Dis
;;^UTILITY(U,$J,358.3,43540,1,4,0)
;;=4^I69.913
;;^UTILITY(U,$J,358.3,43540,2)
;;=^5138663
;;^UTILITY(U,$J,358.3,43541,0)
;;=I69.914^^160^2124^31
;;^UTILITY(U,$J,358.3,43541,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,43541,1,3,0)
;;=3^Front Lobe/Exec Fx Dfct s/p Unsp Crbrovs Dis
;;^UTILITY(U,$J,358.3,43541,1,4,0)
;;=4^I69.914
;;^UTILITY(U,$J,358.3,43541,2)
;;=^5138664
;;^UTILITY(U,$J,358.3,43542,0)
;;=I69.915^^160^2124^15
;;^UTILITY(U,$J,358.3,43542,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,43542,1,3,0)
;;=3^Cog Social/Emot Dfct s/p Crbrvsc Dis
;;^UTILITY(U,$J,358.3,43542,1,4,0)
;;=4^I69.915
;;^UTILITY(U,$J,358.3,43542,2)
;;=^5138665
;;^UTILITY(U,$J,358.3,43543,0)
;;=I69.918^^160^2124^48
;;^UTILITY(U,$J,358.3,43543,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,43543,1,3,0)
;;=3^Sym/Sgns Cog Fxn Dfct s/p Unsp Crbrvsc Dis,Oth
;;^UTILITY(U,$J,358.3,43543,1,4,0)
;;=4^I69.918
;;^UTILITY(U,$J,358.3,43543,2)
;;=^5138666
;;^UTILITY(U,$J,358.3,43544,0)
;;=I69.919^^160^2124^49
;;^UTILITY(U,$J,358.3,43544,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,43544,1,3,0)
;;=3^Sym/Sgns Cog Fxn Dfct s/p Unsp Crbrvsc Dis,Unsp
;;^UTILITY(U,$J,358.3,43544,1,4,0)
;;=4^I69.919
;;^UTILITY(U,$J,358.3,43544,2)
;;=^5138667
;;^UTILITY(U,$J,358.3,43545,0)
;;=I69.993^^160^2124^13
;;^UTILITY(U,$J,358.3,43545,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,43545,1,3,0)
;;=3^Ataxia following unspec Cerebrovasc Disease
;;^UTILITY(U,$J,358.3,43545,1,4,0)
;;=4^I69.993
;;^UTILITY(U,$J,358.3,43545,2)
;;=^5007571
;;^UTILITY(U,$J,358.3,43546,0)
;;=I69.998^^160^2124^16
;;^UTILITY(U,$J,358.3,43546,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,43546,1,3,0)
;;=3^Disturbance of Vision
;;^UTILITY(U,$J,358.3,43546,1,4,0)
;;=4^I69.998
;;^UTILITY(U,$J,358.3,43546,2)
;;=^5007572
;;^UTILITY(U,$J,358.3,43547,0)
;;=I69.992^^160^2124^29
;;^UTILITY(U,$J,358.3,43547,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,43547,1,3,0)
;;=3^Facial Weakness s/p Unspec Cerebrov Dis
;;^UTILITY(U,$J,358.3,43547,1,4,0)
;;=4^I69.992
;;^UTILITY(U,$J,358.3,43547,2)
;;=^5007570
;;^UTILITY(U,$J,358.3,43548,0)
;;=I69.923^^160^2124^30
;;^UTILITY(U,$J,358.3,43548,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,43548,1,3,0)
;;=3^Fluency Disorder s/p Unspec Cerebrov Dis
;;^UTILITY(U,$J,358.3,43548,1,4,0)
;;=4^I69.923
;;^UTILITY(U,$J,358.3,43548,2)
;;=^5007556
;;^UTILITY(U,$J,358.3,43549,0)
;;=I69.951^^160^2124^34
;;^UTILITY(U,$J,358.3,43549,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,43549,1,3,0)
;;=3^Hemiplegia Affecting Rt Dominant Side
;;^UTILITY(U,$J,358.3,43549,1,4,0)
;;=4^I69.951
;;^UTILITY(U,$J,358.3,43549,2)
;;=^5007561
;;^UTILITY(U,$J,358.3,43550,0)
;;=I69.952^^160^2124^32
;;^UTILITY(U,$J,358.3,43550,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,43550,1,3,0)
;;=3^Hemiplegia Affecting Lt Dominant Side
;;^UTILITY(U,$J,358.3,43550,1,4,0)
;;=4^I69.952
;;^UTILITY(U,$J,358.3,43550,2)
;;=^5133586
;;^UTILITY(U,$J,358.3,43551,0)
;;=I69.953^^160^2124^35
;;^UTILITY(U,$J,358.3,43551,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,43551,1,3,0)
;;=3^Hemiplegia Affecting Rt Non-Dominant Side
;;^UTILITY(U,$J,358.3,43551,1,4,0)
;;=4^I69.953
;;^UTILITY(U,$J,358.3,43551,2)
;;=^5007562
;;^UTILITY(U,$J,358.3,43552,0)
;;=I69.954^^160^2124^33
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI2QD 3752 printed Sep 23, 2025@20:09:47 Page 2
IBDEI2QD ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,43540,1,3,0)
+2 ;;=3^Psychomtr Dfct s/p Unsp Cebrvsc Dis
+3 ;;^UTILITY(U,$J,358.3,43540,1,4,0)
+4 ;;=4^I69.913
+5 ;;^UTILITY(U,$J,358.3,43540,2)
+6 ;;=^5138663
+7 ;;^UTILITY(U,$J,358.3,43541,0)
+8 ;;=I69.914^^160^2124^31
+9 ;;^UTILITY(U,$J,358.3,43541,1,0)
+10 ;;=^358.31IA^4^2
+11 ;;^UTILITY(U,$J,358.3,43541,1,3,0)
+12 ;;=3^Front Lobe/Exec Fx Dfct s/p Unsp Crbrovs Dis
+13 ;;^UTILITY(U,$J,358.3,43541,1,4,0)
+14 ;;=4^I69.914
+15 ;;^UTILITY(U,$J,358.3,43541,2)
+16 ;;=^5138664
+17 ;;^UTILITY(U,$J,358.3,43542,0)
+18 ;;=I69.915^^160^2124^15
+19 ;;^UTILITY(U,$J,358.3,43542,1,0)
+20 ;;=^358.31IA^4^2
+21 ;;^UTILITY(U,$J,358.3,43542,1,3,0)
+22 ;;=3^Cog Social/Emot Dfct s/p Crbrvsc Dis
+23 ;;^UTILITY(U,$J,358.3,43542,1,4,0)
+24 ;;=4^I69.915
+25 ;;^UTILITY(U,$J,358.3,43542,2)
+26 ;;=^5138665
+27 ;;^UTILITY(U,$J,358.3,43543,0)
+28 ;;=I69.918^^160^2124^48
+29 ;;^UTILITY(U,$J,358.3,43543,1,0)
+30 ;;=^358.31IA^4^2
+31 ;;^UTILITY(U,$J,358.3,43543,1,3,0)
+32 ;;=3^Sym/Sgns Cog Fxn Dfct s/p Unsp Crbrvsc Dis,Oth
+33 ;;^UTILITY(U,$J,358.3,43543,1,4,0)
+34 ;;=4^I69.918
+35 ;;^UTILITY(U,$J,358.3,43543,2)
+36 ;;=^5138666
+37 ;;^UTILITY(U,$J,358.3,43544,0)
+38 ;;=I69.919^^160^2124^49
+39 ;;^UTILITY(U,$J,358.3,43544,1,0)
+40 ;;=^358.31IA^4^2
+41 ;;^UTILITY(U,$J,358.3,43544,1,3,0)
+42 ;;=3^Sym/Sgns Cog Fxn Dfct s/p Unsp Crbrvsc Dis,Unsp
+43 ;;^UTILITY(U,$J,358.3,43544,1,4,0)
+44 ;;=4^I69.919
+45 ;;^UTILITY(U,$J,358.3,43544,2)
+46 ;;=^5138667
+47 ;;^UTILITY(U,$J,358.3,43545,0)
+48 ;;=I69.993^^160^2124^13
+49 ;;^UTILITY(U,$J,358.3,43545,1,0)
+50 ;;=^358.31IA^4^2
+51 ;;^UTILITY(U,$J,358.3,43545,1,3,0)
+52 ;;=3^Ataxia following unspec Cerebrovasc Disease
+53 ;;^UTILITY(U,$J,358.3,43545,1,4,0)
+54 ;;=4^I69.993
+55 ;;^UTILITY(U,$J,358.3,43545,2)
+56 ;;=^5007571
+57 ;;^UTILITY(U,$J,358.3,43546,0)
+58 ;;=I69.998^^160^2124^16
+59 ;;^UTILITY(U,$J,358.3,43546,1,0)
+60 ;;=^358.31IA^4^2
+61 ;;^UTILITY(U,$J,358.3,43546,1,3,0)
+62 ;;=3^Disturbance of Vision
+63 ;;^UTILITY(U,$J,358.3,43546,1,4,0)
+64 ;;=4^I69.998
+65 ;;^UTILITY(U,$J,358.3,43546,2)
+66 ;;=^5007572
+67 ;;^UTILITY(U,$J,358.3,43547,0)
+68 ;;=I69.992^^160^2124^29
+69 ;;^UTILITY(U,$J,358.3,43547,1,0)
+70 ;;=^358.31IA^4^2
+71 ;;^UTILITY(U,$J,358.3,43547,1,3,0)
+72 ;;=3^Facial Weakness s/p Unspec Cerebrov Dis
+73 ;;^UTILITY(U,$J,358.3,43547,1,4,0)
+74 ;;=4^I69.992
+75 ;;^UTILITY(U,$J,358.3,43547,2)
+76 ;;=^5007570
+77 ;;^UTILITY(U,$J,358.3,43548,0)
+78 ;;=I69.923^^160^2124^30
+79 ;;^UTILITY(U,$J,358.3,43548,1,0)
+80 ;;=^358.31IA^4^2
+81 ;;^UTILITY(U,$J,358.3,43548,1,3,0)
+82 ;;=3^Fluency Disorder s/p Unspec Cerebrov Dis
+83 ;;^UTILITY(U,$J,358.3,43548,1,4,0)
+84 ;;=4^I69.923
+85 ;;^UTILITY(U,$J,358.3,43548,2)
+86 ;;=^5007556
+87 ;;^UTILITY(U,$J,358.3,43549,0)
+88 ;;=I69.951^^160^2124^34
+89 ;;^UTILITY(U,$J,358.3,43549,1,0)
+90 ;;=^358.31IA^4^2
+91 ;;^UTILITY(U,$J,358.3,43549,1,3,0)
+92 ;;=3^Hemiplegia Affecting Rt Dominant Side
+93 ;;^UTILITY(U,$J,358.3,43549,1,4,0)
+94 ;;=4^I69.951
+95 ;;^UTILITY(U,$J,358.3,43549,2)
+96 ;;=^5007561
+97 ;;^UTILITY(U,$J,358.3,43550,0)
+98 ;;=I69.952^^160^2124^32
+99 ;;^UTILITY(U,$J,358.3,43550,1,0)
+100 ;;=^358.31IA^4^2
+101 ;;^UTILITY(U,$J,358.3,43550,1,3,0)
+102 ;;=3^Hemiplegia Affecting Lt Dominant Side
+103 ;;^UTILITY(U,$J,358.3,43550,1,4,0)
+104 ;;=4^I69.952
+105 ;;^UTILITY(U,$J,358.3,43550,2)
+106 ;;=^5133586
+107 ;;^UTILITY(U,$J,358.3,43551,0)
+108 ;;=I69.953^^160^2124^35
+109 ;;^UTILITY(U,$J,358.3,43551,1,0)
+110 ;;=^358.31IA^4^2
+111 ;;^UTILITY(U,$J,358.3,43551,1,3,0)
+112 ;;=3^Hemiplegia Affecting Rt Non-Dominant Side
+113 ;;^UTILITY(U,$J,358.3,43551,1,4,0)
+114 ;;=4^I69.953
+115 ;;^UTILITY(U,$J,358.3,43551,2)
+116 ;;=^5007562
+117 ;;^UTILITY(U,$J,358.3,43552,0)
+118 ;;=I69.954^^160^2124^33
